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Background: Postherpetic neuralgia (PHN) is a chronic neuropathic pain that results from alterations of the
peripheral nervous system in areas affected by the herpes zoster virus. The symptoms include pain, paresthesia,
dysesthesia, hyperalgesia, and allodynia. Despite the availability of pharmacological treatments to control these
symptoms, no treatments are available to control the underlying pathophysiology responsible for this disabling
condition.
Methods/design: Patients with herpes zoster who are at least 50 years old and have a pain score of 4 or higher
on a visual analogue scale (VAS) will be recruited. The aim is to recruit 134 patients from the practices of general
physicians. Participants will be randomized to receive gabapentin to a maximum of 1800 mg/day for 5 weeks or
placebo. Both arms will receive 1000-mg caplets of valacyclovir three times daily for 7 days (initiated within 72 h
of the onset of symptoms) and analgesics as needed. The primary outcome measure is the percentage of patients
with a VAS pain score of 0 at 12 weeks from rash onset. The secondary outcomes measures are changes in quality
of life (measured by the SF-12 questionnaire), sleep disturbance (measured by the Medical Outcomes Study Sleep
Scale), and percentage of patients with neuropathic pain (measured by the Douleur Neuropathique in 4 Questions).
Discussion: Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its
antihypersensitivity action in dorsal horn neurons.
Trial registration: ISRCTN Registry identifier: ISRCTN79871784. Registered on 2 May 2013.
Keywords: Postherpetic neuralgia, Gabapentin, Herpes zoster, Prevention, Primary health careBackground
Herpes zoster (HZ), often called shingles, is a common
disease characterized by a painful, unilateral vesicular
eruption that is caused by reactivation of a dormant
varicella zoster virus within the dorsal root or cranial
nerve ganglia. The most frequent complication following
an acute episode of HZ infection is postherpetic neuralgia
(PHN), a chronic and debilitating neuropathic pain syn-
drome that is refractory to most therapeutic strategies.* Correspondence: aleiva@ibsalut.caib.es
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(http://creativecommons.org/publicdomain/zePHN is considered a clinically significant problem
because it may last for years and because it negatively
impacts a patient’s quality of life across all four health
domains: physical, psychological, functional, and social.
The symptoms associated with PHN are sleep distur-
bances, mood changes, depression, and anxiety [1].
The authors of a recent systematic review reported
that the incidence of HZ infection was between 3 and 12
cases per 1000 patient-years for individuals older than
50 years of age, and that the overall risk of PHN ranges
from 5% to more than 30% [2]. Differences in the
reported incidence of PHN are due to the lack of
consensus on the definition of PHN (i.e., use of different
durations of persisting pain from the onset of shingles
for a positive diagnosis) and differences in the agele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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as pain lasting for 3 months, the incidence is 18% in
individuals older than 50 years of age and 33% in
individuals older than 80 years of age [3].
The development of PHN is associated with increased
patient age and severity of acute pain [4]. The diversity
of the PHN symptoms (pain, paresthesia, dysesthesia,
hyperalgesia, and allodynia) seems to be related to a
variety of underlying changes in the nervous system, but
this is still unclear. HZ infection is associated with
damage to the central and peripheral nervous systems.
Although the pathophysiology of PHN is incompletely
understood, two possible mechanisms could be respon-
sible: sensitization (peripheral and central neuron gen-
eration of spontaneous discharges) and deafferentation
(neural damage and inflammation with subsequent
edema) [5]. In addition, previous research indicated
severe depletion of epidermal free nerve endings in the
skin biopsies of patients with PHN, and authors of
postmortem studies reported atrophy of the spinal
dorsal root ganglia, demyelination with fibrosis, and cell
loss [6].
Gabapentin, a structural analogue of γ-aminobutyric
acid, has been used for the treatment of PHN for de-
cades, and the results of several randomized controlled
trials (RCTs) show that it is a well-tolerated and effica-
cious treatment in patients with PHN [7]. However,
gabapentin used for the prevention of PHN has shown
contradictory results. Researchers in an uncontrolled,
open-label study reported that administration of gaba-
pentin plus valacyclovir during the acute phase of HZ
infection reduced the incidence of PHN [8]. A more
recent prospective, controlled, two-armed study using
low doses of gabapentin and valacyclovir showed no
statistical differences between the two groups regarding
PHN prevention [9].
The primary objective of the present study is to evaluate
the efficacy of an optimal dose of gabapentin added to the
usual treatment—valacyclovir and analgesics as neede-
d—in the prevention of PHN at 12 weeks in patients older
than 50 years old who have moderate to severe pain.Methods/design
Design and setting
We designed a multicenter, parallel, randomized, double-
blind, placebo-controlled trial with recruitment of 134
patients from 17 primary care centers in Mallorca, Spain.
Participants will be randomly allocated to receive
gabapentin or placebo for 8 weeks to evaluate the ef-
ficacy of gabapentin in the prevention of PHN.
Figure 1 summarizes the study design and time line,
and Fig. 2 displays the schedule of enrollment, inter-
ventions, and assessments.Study population
Male or female patients who are at least 50 years old, have
a clinical diagnosis of uncomplicated HZ, present within
the first 72 h of vesicle formation, and have an average pain
score of at least 4 on a visual analogue scale (VAS) before
therapy will be recruited. Table 1 summarizes the eligibility
criteria. The study methods are in accordance with the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) statement (Additional file 1).
Recruitment
Each participating primary care center will have at least
one physician from the research team invite potential
candidates to participate in the clinical trial and to per-
form all procedures. All patients diagnosed with acute
HZ will be referred to this physician and will be invited
to participate in the trial. Willing participants who meet
the eligibility criteria will be enrolled after they read and
sign an informed consent agreement (Additional file 2).
Randomization
The central pharmacy of Hospital Son Espases will pack-
age the study treatments (placebo or gabapentin) using
an unblinded randomization code list. The link between
the randomization code and the corresponding treat-
ment will remain blinded for all other study team mem-
bers. During the process of randomization, each subject
will be assigned a randomization code and will be given
the treatment package with that code. This sequential
randomization will be generated in blocks of six. To assess
the effectiveness of masking, patients and investigators
will be asked to guess whether they think they received
the treatment or placebo at the final visit, and then will be
asked to indicate what led them to that belief.
Intervention
The primary goals in management of HZ are to inhibit
ongoing viral replication, alleviate pain, and prevent
complications such as local shingles infections or PHN
[10]. Local measures to prevent vesicle infection will be
recommended to all recruited patients. These measures
include frequent hand-washing, drying out of shingles
after a shower without scratching the blisters, and cover-
ing blisters until they are crusted over.
Antiviral therapy is considered the firstline treatment
for HZ and should be initiated within 72 h of onset.
Thus, all participants will receive 1000-mg caplets of
valacyclovir hydrochloride three times daily for 7 days.
The World Health Organization three-step pain relief
ladder will be used for pain management. In particu-
lar, if pain occurs, there will be prompt oral adminis-
tration of drugs in the following order, until the
patient is free of pain: nonopioids (paracetamol); then,
Fig. 1 Study time line and flowchart of participants. IC Informed consent
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oids, such as morphine.
Study medication
Bottles of 300-mg gabapentin capsules and of matching
placebos will be dispensed according to the randomization
schedule, which is retained by the clinical trial pharmacist.
The participants, research staff, and investigators who
assess outcomes will be masked to treatment allocations.
Gabapentin will be initiated at 300 mg/day and then
increased in a stepwise manner according to the instruc-
tions for use. The dose will be increased, regardless of
whether efficacy is achieved at a lower dose, to a ceiling
daily dose of 1800 mg/day. In patients who develop
intolerable adverse effects, the dose will be reduced. The
optimal dose established during the titration period will
be maintained throughout the remainder of the study and
followed by 1 week of dose-tapering. Use of systemic
corticosteroids and tricyclic antidepressants will not be
allowed.
Assessing medication adherence
The treatment will be monitored at every visit by the
responsible physician at every participating health care
center. We will ask the patients to comply with a
medical diary that has to be followed until the next
appointment or a daily medication box, if wanted. At the
last visit, the participants must return their bottles, anda final count will be made by the physician. A biannual
study newsletter will be sent to all the researchers, and
an annual meeting will take place between the principal
investigator and all the study collaborators.
Data collection methods and record-keeping
Case report forms will be used to record data for all
participants. The researchers will receive training for
standardized data collection procedure. All data will be
stored in a locked cabinet of every researcher until the
inclusion period finishes. Patient information will be
coded using a unique numerical identification, and the
data will be entered into an electronic database and its
validity secured. Logical checks will be performed for
missing data and to find inconsistencies. The researchers
and data analysts will have full access to data.
Measurement of outcomes
Measures and variables are summarized, with a timeline,
in Table 2. The main outcome measure will be the inci-
dence of PHN at 12 weeks, defined as an average daily
VAS pain score of 0.
Secondary outcome variables
Response rate The response rate of the groups at 6 and
12 weeks is a secondary outcome measure. Responders
will be defined as those with a 50% reduction in VAS
pain compared with baseline. This outcome was chosen
Fig. 2 Schedule of enrollment, interventions, and assessments. MOS Medical Outcomes Study
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Table 1 Patient eligibility criteria for assessment of the efficacy of gabapentin in prevention of postherpetic neuralgia
Inclusion criteria Exclusion criteria
Male or female, at least 50 years old Patients taking gabapentin or a tricyclic antidepressant
Patients with diagnoses of uncomplicated herpes zoster
presenting within the first 72 h of vesicle formation and
an average pain score of at least 4 on a visual analogue
scale of pain before therapy
Patients with evidence of cutaneous or visceral dissemination of herpes
zoster infection (cutaneous dissemination is defined as more than 20
discrete lesions outside adjacent dermatomes) or ocular involvement
of herpes zoster
Patients who are willing and able to comply with the
requirements of the study
Patients with histories of intolerance or hypersensitivity to any active
components of or excipient from the study drugs
Patients who are willing and able to give written
informed consent
Patients with severe hepatic impairment or impaired renal function
(creatinine clearance <79 ml/minute)
Patients who have received cytotoxic drugs or immunosuppressive therapy
within the previous 3 months (e.g., long-term systemic corticosteroids)
Patients with any diagnosed immune dysfunction
Patients who have received immunomodulatory medications (including
interferon) within the previous 4 weeks
HZ vaccine immunization
HZ Herpes zoster
Rullán et al. Trials  (2017) 18:24 Page 5 of 9following a recommendation from the Committee for
Medicinal Products for Human Use in their clinical
guidelines on clinical medicinal products intended for
the treatment of neuropathic pain [11].
Percentage of patients with neuropathic pain (Douleur
Neuropathique in 4 Questions) The change from base-
line to the end of the study in the DN4 questionnaire
(Douleur Neuropathique in 4 Questions) score will be
used to assess changes in neuropathic pain. This scale
includes ten items, with each “yes” response scored as 1,
and is subdivided into descriptors (seven items) and
signs relating to the sensory examination (three items).
A score above 4 indicates neuropathic pain. This ques-
tionnaire has been validated previously [12, 13], and a
validated Spanish version is available [14].Table 2 Instruments, assessments, and timing of assessments
Instrument Assessment
Sampling form Inclusion/exclusion criteria
Sociodemographic data form Sociodemographic data (age, sex, BMI)
Baseline clinical data form Medical history, concomitant medicatio
control HZ-related pain
Visual analogue scale pain score Severity of pain before/after therapy
SF-12 questionnaire Health-related quality of life
Monitor adherence Indirect method: patient questionnaires
Adverse events Adverse event evaluations related to st
MOS Sleep Scale Extent of sleep problems (sleep initiatio
quantity, perceived adequacy, and som
DN4 Neuropathic pain consisting of intervie
Analgesic consumption form Total consumption of analgesic drugs d
Number of patients on analgesics at th
Abbreviations: BMI Body mass index, DN4 Douleur Neuropathique in 4 Questions, HZ
Health SurveyQuality of life The 12-item Short Form Health Survey
(SF-12®), a short version of the SF-36®, will be used to as-
sess quality of life. This questionnaire has two questions
on physical functioning, two questions on role limitations
because of physical health problems, one question on
bodily pain, one question on general health perceptions,
one question on vitality (energy/fatigue), one question on
social functioning, two questions on role limitations
because of emotional problems, and two questions on
general mental health (psychological distress and
psychological well-being). The SF-12 is applicable in
different cultures, and a validated Spanish version is
available [15, 16].
Sleep interference The Medical Outcomes Study Sleep
Scale will be used to assess the quality and quantity ofTime of assessment
Before randomization
Baseline
ns, and analgesic drugs to Baseline, 1, 4, 6, and 12 weeks
Baseline, 4, 6, and 12 weeks
Baseline and 12 weeks
, patient self-reports, and pill counts 12 weeks
udy medication 1, 4, 6, and 12 weeks
n, maintenance, respiratory problems,
nolence)
Baseline and 12 weeks
w questions and physical tests Baseline and 12 weeks
uring the study period 12 weeks
e end of the study
Herpes zoster, MOS Medical Outcomes Study, SF-12 12-item Short Form
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key constructs of sleep. It is self-administered, and
patients are asked to recall sleep-related activities over
the past 4 weeks. It comprises scoring in six domains:
sleep disturbance (four items), snoring (one item), awak-
ening with shortness of breath or a headache (one item),
quantity of sleep (one item), optimal sleep (one item),
sleep adequacy (two items), and daytime somnolence
(three items). This scale has been validated in Spanish
for patients with neuropathic pain [17].Patient Global Impression of Change Scale The
Patient Global Impression of Change Scale comprises a
single question in which the patient is asked to rate his/
her present condition relative to how it was prior to
treatment on a scale from 1 (very much better) to 7
(very much worse). This scale has been used in previous
studies in which researchers assessed patients’ impres-
sions of improvement following PHN treatment [18].Analgesic consumption Medications taken for control
of pain will be recorded at baseline and at every follow-
up visit during the study period.Safety
Patients will be interviewed at each study visit regarding
the occurrence of any adverse events (AEs), including
type of event, time of onset, duration, and severity.
Safety analyses will be performed on the safety popula-
tion, which will consist of all patients who received at
least one dose of the study drug. Safety data will include
the incidence of treatment-emergent AEs, serious ad-
verse events (SAEs), and the number and percentage of
patients reporting one or more AEs in each group.Withdrawals
Participants will be free to withdraw from participation
at their own request at any time without giving reasons
for their decision. Withdrawals will be documented in
the case report forms and in patients’ medical records,
with active follow-up for ongoing SAEs.Adverse effects
All information regarding AEs will be presented in
the case report form. The study investigators will
investigate the causal relationship of the study drug and
the intensity of AEs. Any SAE (e.g., death, a life-
threatening event, inpatient hospitalization or prolonga-
tion of existing hospitalization, persistent or significant
disability/incapacity) in any patient during the course of
the study will be reported to the ethics committee [19].Sample size
The sample size calculation is based on the primary
outcome measure and the primary analysis for the
intention-to-treat population. Researchers in a previous
nonrandomized, noncontrolled experimental study
reported the incidence of PHN was 20% [8]. Thus, we
estimated a 45% incidence of PHN in the placebo group,
based on its incidence in patients older than 50 years old
with an average VAS pain score of 4 or more reported in a
longitudinal study [20]. We adjusted the sample size for an
estimated follow-up loss rate of 20% and a 0.05 two-sided
level of significance (α = 5%). Thus, we will need 67 patients
in each group to detect a difference of at least 25% in the
incidence of PHN in the treatment and placebo arms.
Statistical analysis
We will test for significant baseline differences in the pla-
cebo and gabapentin arms by use of descriptive analysis,
with continuous variables summarized by means and SDs
for normal distributions and by medians and 25th and
75th percentiles for nonnormal distributions. All analyses
of the effectiveness and cost-effectiveness will involve
intention-to-treat populations (i.e., all randomized pa-
tients, regardless of participation in any treatment ses-
sion). This approach reduces the bias that may occur
when participants not receiving assigned treatments are
excluded from analysis. All tests will be two-sided, and an
α value of 0.05 will be considered statistically significant.
We will compare the proportions of patients in each
arm with PHN at 12 weeks against the null hypothesis
of no difference between the groups. We will use the
chi-square test in multivariate analysis and will adjust
for potential confounders, if any, using a logistic regres-
sion model. We will estimate relative and absolute risk
reduction and the number needed to treat, defined as
the estimated number of patients who need to be treated
with gabapentin for prevention of PHN in one patient.
The health economic analysis will be performed by cal-
culating the incremental cost-effectiveness ratio (ICER) at
12 weeks. We will systematically collect data on use of all
resources, including inpatient care, consultations with
health care providers, use of drugs, and laboratory tests.
To measure effects, the SF-12 scores will be transformed
into EQ-5D utility scores and quality-adjusted life-years
(QALYs) will be determined. The ICER will be calculated
as the difference in the mean costs of the two groups di-
vided by difference in the mean effects of the two groups:
ICER ¼ CI−CT
EI−ET
A nonparametric bootstrap procedure will be used to
perform the uncertainty analysis for the ICER. This
procedure considers the skewness of cost data and the
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confounding variables and to account for clustering, an
alternative procedure (net-benefit regression) will also be
used. Cost-effectiveness acceptability curves will be cre-
ated to illustrate statistical uncertainty. We will deter-
mine the safety of interventions in the safety population
and use per-protocol analysis with the chi-square test by
comparing the AEs among patients.
All estimates will include 95% confidence intervals.
The number needed to treat will be calculated as the
reciprocal of the difference between the proportion of
patients with PHN in the placebo and gabapentin arms.
Approval
This study will follow the principles outlined in the
Declaration of Helsinki. All patients will be asked to
provide written informed consent and will be told that
participation is voluntary and can be withdrawn at any
time without any negative consequences concerning
their current or future medical treatments. Our study
protocol has been approved by the Primary Care
Research Committee, the Mallorca Ethical Committee of
Clinical Research (IB 1857/12), and the Spanish Agency
on Drugs and Medical devices (for Agencia Española de
Medicamentos y Productos Sanitarios). Any protocol
modification will be approved by the executive commit-
tee, submitted to the ethics committee for approval, and
noted to the ISRCTN registry. Trial participants will be
notified if relevant protocol changes will be made.
Discussion
PHN is a persistent nerve pain that has an adverse effect
on quality of life in patients with HZ. It has a high preva-
lence among patients with HZ who are older than 50 years
old and in those with moderate to severe pain, although
previous studies have used different definitions of PHN.
The definition of PHN in the proposed study is persistent
pain for more than 90 days since the onset of shingles,
considered the most accepted definition for PHN [21, 22].
Treatments for PHN attempt to alleviate the pain, and
several pharmacological strategies are available. This in-
cludes tricyclic antidepressants, anticonvulsants, analge-
sics, and topical agents. However, no disease-modifying
therapy is available [23], and preventive strategies are
urgently needed. Preventive strategies such as varicella
zoster virus live-attenuated vaccine (approved by the
U.S. Food and Drug and Administration for adults older
than 50 years old) showed reductions of the incidence of
HZ infection and PHN [22], but RCTs are needed to
confirm these results.
Gabapentin acts on supraspinal region to stimulate
noradrenaline-mediated descending inhibition [24–26].
We hypothesize that preventing central sensitization in
patients with HZ will reduce the incidence of PHN.Thus, gabapentin may provide pain relief, but whether
pain relief could also prevent the onset of PHN is not
yet clear. In our study, participants in both arms will
receive analgesic treatments as needed to provide pain
relief. There is a significant increase in the risk of PHN
following acute zoster infection, including prodromal
pain and severe rush. Thus, participants in both of our
study arms will also receive valacyclovir within 72 h after
rash appearance. Valacyclovir is preferred over other
antivirals because it more easily produces consistently
high levels in the blood, patient compliance is better,
and less frequent dosing is required.
The effectiveness of gabapentin for the prevention of
NPH was previously evaluated in two studies. Re-
searchers in an uncontrolled open-label study concluded
that the combination of gabapentin and valacyclovir re-
duces the incidence of PHN [8]; however, although the
gabapentin dose could be titrated up to 3600 mg/day,
only a few patients reached that dose, and the median
dose was 1085 mg/day for 34 days. This study was
criticized because there was no control group; instead,
the authors compared the incidence of PHN with his-
toric control subjects described in a meta-analysis of six
RCTs of antiviral agents used to treat acute zoster infec-
tion [27]. These authors also concluded that larger-scale
blinded studies are necessary to confirm their results.
A prospective controlled study showed that low doses
of gabapentin were not effective in the prevention of
PHN [9]. However, the study was nonrandomized, and
patients were not blinded to treatment.
The two main strengths of our study are that, as far as
we know, it is the first RCT to examine the effect of
gabapentin on prevention of PHN, and it is an inde-
pendent clinical trial funded by a public research agency.
The ceiling dose of gabapentin is 1800 mg/day because
it has been established that a dose greater than
1800 mg/day does not generally provide greater benefit;
the bioavailability of gabapentin varies inversely with
dose, and high-dose regimens are associated with lower
patient compliance [28]. Gabapentin is compared with
placebo treatment because there is no convincing
evidence that other treatments can reduce PHN after
HZ has been established. Currently, the management of
HZ and PHN is based largely on general practice. This
RCT is developed entirely in a primary care setting and
will have the participation of 17 primary care teams.
The external validity will be assured because the effect-
iveness of gabapentin treatment in the prevention of
PHN will be assessed in the same settings in which
most HZ cases are treated.
Limitations of our study include the possibility of a
high discontinuation rate due to gabapentin’s potential
side effects, possible interactions of gabapentin with
other drugs, and the complex dosage regimen. The most
Rullán et al. Trials  (2017) 18:24 Page 8 of 9recognizable side effects of gabapentin are dizziness,
somnolence, and drowsiness, so their presence might com-
promise the blinding of patients and investigators.
Although we considered the use of an active placebo (a pla-
cebo that mimics the side effects of the drug under evalu-
ation), we finally decided to use a “pure” placebo because of
ethical considerations for the patients included in the study.
HZ and PHN have major impacts on patients’ lives
[29] and constitute a significant economic burden for
health care systems and societies at large [30]. A treat-
ment that effectively prevents PHN in patients at high
risk could improve the quality of life of patients with HZ
and also reduce health care costs.
Trial status
At the time of this writing, 70% of the target population
of 134 has been enrolled. The anticipated study comple-
tion date is January 2017.
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